Karen Firestone, chairman and CEO at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest portfolio moves.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Drugmaker Abbott India reported a rise in first-quarter profit on Wednesday, helped by higher sales and price hikes.

Unique partnership with Medtronic will enable continuous glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre sensing technology to integrate with Medtronic's insulin delivery systems Abbott now has partnerships with four of the largest companies that develop automated insulin delivery systems – offering more choices to people around the world to benefit from connectivity with Libre technology ABBOTT PARK, Ill., Aug. 7, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading1 FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.

Abbott Labs is a proven wealth builder at a fair price. Johnson & Johnson's a safe buy despite its ongoing litigation.

PONTE VEDRA, Fla., Aug. 6, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, announced today that it has been in discussions with Abbott (NYSE: ABT) about Cadrenal's planned pivotal study of tecarfarin in patients with recently implanted LVADs.

Abbott Laboratories is now a $183 billion (by market cap) healthcare titan. Abbott Laboratories has increased its dividend for more than 50 consecutive years. So it has the kind of dividend growth pedigree that few companies can compare to. The company has increased its revenue from $20.2 billion in FY 2014 to $40.1 billion in FY 2023. That's a solid compound annual growth rate of 7.9%.

Abbott Laboratories and Gilead Sciences are solid dividend stocks. Both look a bit pricey relative to their recent financial results.

Abbott (ABT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ABT broke through the 200-day moving average, which suggests a long-term bullish trend.

The diabetes donnybrook between Abbott Laboratories and Dexcom is poised to heat up — and could bolster both Abbott stock and Dexcom stock.

Johnson & Johnson has been generating decent growth, but legal challenges could create a lot of uncertainty. Abbott Laboratories has a more diverse business, with some exciting opportunities in diabetes care.

While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.